Compare IDEXX Laboratories, Inc. (IDXX) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Rivian Automotive, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Rivian Automotive, Inc. trades at $17.62 (market cap $24.95B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | RIVN | |
|---|---|---|
Market Cap | $44.48B | $24.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $22.45 |
52-Week Low | $520.87 | $11.64 |
Enterprise Value | $45.38B | $26.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Rivian Automotive (RIVN) trades at $17.19, down 1.52% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company continues to post significant losses, with a net income margin of -63.62% for 2025, though revenue growth has been steady and recent quarterly EPS have beaten expectations. Cash flow remains negative, but the trend shows improvement from prior years. Analyst sentiment is mixed with a consensus price target of $19.22.
The outlook hinges on successful execution of the R2 vehicle launch and path to profitability. Investment opportunity lies in the potential for market share gains in the EV sector, but risks include high cash burn, competitive pressures, and reliance on capital markets for funding. The stock's performance will be closely tied to quarterly earnings and production updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
